Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam
Nov 28, 2016 12:00 pm UTC| Business
IV Meloxicam Achieves Primary Endpoint of Statistically Significant Reduction in SPID24 in Patients with Acute Postoperative Pain Following Abdominoplasty Surgery Ten Secondary Endpoints Also MetCompany Estimates Filing US...
Nov 28, 2016 12:00 pm UTC| Business
MEXICO CITY, Nov. 28, 2016 -- Empresas ICA, S.A.B. de C.V. (BMV:ICA), announced today its unaudited results for the third quarter of 2016, which have been prepared in accordance with International Financial Reporting...
Nov 28, 2016 12:00 pm UTC| Business
Conference Call Today at 4:30 p.m. ET Highlights: Sales for the third quarter of 2016 increased 15.4% compared to the third quarter of 2015Closed $150 million follow-on public offering and subsequent underwriters option...
Akoustis™ Co-Chairman, Jerry Neal, Leads $1.61 Million Financing Round
Nov 28, 2016 12:00 pm UTC| Business
Charlotte, N.C., Nov. 28, 2016 -- Akoustis Technologies, Inc. (OTCQB: AKTS) (“Akoustis” or the “Company”), a manufacturer of patented BulkONE™ bulk acoustic wave (BAW) high band RF filters for mobile wireless, announced...
Immunomedics Postpones 2016 Annual Meeting of Stockholders
Nov 28, 2016 12:00 pm UTC| Business
MORRIS PLAINS, N.J., Nov. 28, 2016 -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or “the Company”) today announced that, after careful consideration and in light of venBio Select Advisors LLC’s (“venBio”) recently...
LKQ Corporation to Acquire Equity Interest in Mekonomen Group
Nov 28, 2016 12:00 pm UTC| Business
CHICAGO, Nov. 28, 2016 -- LKQ Corporation (Nasdaq:LKQ) today announced that it has entered into an agreement to acquire an equity interest in Mekonomen AB (STO:MEKO) from Axel Johnson AB (“AXJ”). Headquartered in...
Anavex Life Sciences Appoints Three Distinguished Researchers To Scientific Advisory Board
Nov 28, 2016 12:00 pm UTC| Business
NEW YORK, Nov. 28, 2016 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative...